PLx Pharma Inc.

NASDAQ:PLXP  
5.46
-0.14 (-2.50%)
Earnings Announcements

Plx Pharma Inc. Reports Third Quarter 2020 Results And Provides Business Update

Published: 11/16/2020 23:30 GMT
PLX Pharma Inc (PLXP) - .
Reports Third Quarter 2020 Results and Provides Business Update.
Q3 Loss per Share $0.40.
On Target for Q3 2021 Commercial Launch of Vazalore.
Recognized No Revenue for Three Months Ended September 30, 2020.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.29

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be $0.00

More details on our Analysts Page.